Deniz Tschammler

Partner

Frankfurt
deniz.tschammler@lw.com
+49.69.6062.6000

PRACTICES

  • Emerging Companies & Growth
  • Privacy & Cyber
  • Private Equity
  • Technology Transactions
  • White Collar Defense & Investigations

INDUSTRIES

  • Artificial Intelligence
  • Digital Health
  • Healthcare & Life Sciences
  • Technology

BAR QUALIFICATIONS

  • Rechtsanwalt (Germany)

EDUCATION

  • Executive MBA, University of St. Gallen, 2021
  • LLM, King's College London, 2013
  • Second State Exam, Regional Court, Wiesbaden, 2012
  • Dr. jur., University of Marburg, 2011
  • First State Exam, Goethe University of Frankfurt, 2008

PROFILE

Dr. Deniz Tschammler, a leading lawyer within the European healthcare market, advises clients on a full spectrum of industry-specific matters, with a particular focus on complex transactions and major industrial projects.

Deniz leverages extensive experience to guide pharmaceutical and medical technology companies, providers of digital health solutions, and their investors on:

  • Transactions and collaborations in the healthcare and life sciences market
  • Regulation of pharmaceuticals, medical devices and digital health products across their life cycle
  • Digitization projects and the handling of health data
  • Disruptive business models and competition strategies
  • Healthcare compliance, supply chain management, and general compliance management
  • Industry-specific legal disputes and internal investigations

He regularly advises on cross-border projects, including foreign trade law and foreign investment control matters.

EXPERIENCE

Deniz’s experience includes advising:

  • Oakley Capital on acquiring Flemming Dental, Excent & Artinorway Group*
  • Elos Medtech on its merger with Klingel Medical Group*
  • Myonex on acquiring Hubertus Pharmacy’s clinical trial business*
  • AUCTUS Capital Partners AG on selling PharmaLex Group*
  • Lifespin on concluding a research cooperation with Biobank Graz and the Clinical Department of Oncology at Medical University of Graz*
  • STADA Arzneimittel AG on a licensing collaboration with Calliditas Therapeutics AB for approving and marketing a novel specialty pharmaceutical candidate*
  • Merck KGaA on negotiating a cooperation agreement with neuroloop GmbH, an early-stage startup company of B. Braun Group*

*Matter handled prior to joining Latham